A method of treating calcific aortic valve disease (CAVD), such as aortic valve sclerosis or stenosis, comprises administering an immunosuppressive drug or therapy to CAVD patient to slow or prevent progression of CAVD. Individuals who do not have cardiovascular disease may benefit particularly from the method described. The presence of antibody or Infiltration of immune cells into aortic valve tissue may be slowed or prevented using the method described. Uses and kits for addressing CAVD are also provided. Immunosuppressive drugs or therapies comprise but are not limited to steroids, glucocorticoids methotrexate, mycophenolate mofetil, Rituximab, anti-CD 20 monoclonal antibodies, anti-macrophage monoclonal antibodies, azathioprine, cyclosporine, leflunomide, cyclophosphamide, chlorambucil, nitrogen mustard, hydroxychloroquine, sulfasalazine, tacrolimus, or rapamycin.
